Skyworks Receives All Necessary Clearances for Proposed Combination with Qorvo

IRVINE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — Skyworks Solutions, Inc. (Nasdaq: SWKS) today announced that it has received all necessary regulatory clearances to proceed with the previously announced transaction with Qorvo, Inc. (Nasdaq: QRVO) (the “Mergers”). The parties expect to close the Mergers on or about October 5, 2026, subject to the satisfaction or waiver of the remaining customary closing conditions.

Integer Receives Early Termination of Hart-Scott-Rodino Waiting Period for Pending Acquisition by KKR

PLANO, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”), a leading global medical device contract development and manufacturing organization (CDMO), today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with the previously announced acquisition of Integer by an affiliate of investment funds managed by KKR (the “Merger”).

ENT & Allergy Associates Expands Pennsylvania Footprint with Melissa Schwartz, DO, and New Elkins Park Clinical Site

ENT & Allergy Associates of Pennsylvania today announced the addition of otolaryngologist Melissa Schwartz, DO, and her established clinical practice at 375 Township Line Road in Elkins Park, PA, effective January 1, 2027.

ENT & Allergy Associates of Pennsylvania today announced the addition of otolaryngologist Melissa Schwartz, DO, and her established clinical practice at 375 Township Line Road in Elkins Park, PA, effective January 1, 2027.

Italfarmaco Presents New Givinostat (Duvyzat®) Clinical Data Supporting Preservation of Upper Limb Function in Duchenne Muscular Dystrophy Patients at the 2026 World Muscle Society Congress

MILAN, Italy, September 30, 2026 – Italfarmaco S.p.A. today announced new long-term data from the ongoing Phase 3 EPIDYS open-label extension (OLE) study showing that treatment with givinostat (Duvyzat®) may help preserve upper limb function in boys with Duchenne muscular dystrophy (DMD). The findings, presented at the 31st Annual International Congress of the World Muscle Society (WMS), provide further evidence supporting the long-term clinical benefits of givinostat across multiple measures of disease progression.

John Brandsema, MD, Paediatric Neurologist in the Division of Neurology at Children’s Hospital of Philadelphia, presented the poster “Trajectory of Performance of Upper Limb in Patients With Duchenne Muscular Dystrophy Treated With Givinostat Relative to a Modeled Natural History Cohort from a Single Centre,” which compared upper limb function in givinostat-treated patients with counterfactual trajectories estimated from an external natural history-based model representing predicted disease progression in the absence of treatment, using the Performance of Upper Limb 2.0 (PUL 2.0) assessment. Upper limb function is an increasingly important measure of disease progression as DMD advances and loss of ambulation occurs.

“Preserving upper limb function is critically important for people living with Duchenne because it directly affects independence and the ability to perform everyday activities,” said Scott Baver, PhD, VP, Head of Global Medical Affairs, Rare Diseases. “These new findings extend our understanding of givinostat beyond ambulatory outcomes and provide exploratory evidence suggesting a potential effect on the preservation of upper limb function, an important aspect of disease progression for people living with DMD.”

“Upper limb function becomes increasingly important as Duchenne progresses because it has a direct impact on independence and participation in daily life,” said John Brandsema, MD, Paediatric Neurologist at Children’s Hospital of Philadelphia and presenter of the analysis. “Preserving upper limb function is an outcome that matters greatly to patients and families.” 

Key findings:
These exploratory analyses compared observed outcomes in patients receiving givinostat with predicted outcomes generated from an external natural history-based model and should be interpreted within the context of this study design.